Open-Label, Part-Randomized Study Designed to Evaluate the PK Profile of Tenofovir Exalidex (TXL) Following Single Dose of Oral Formulations in Comparison to a Reference IR TXL Tablet in Healthy Subjects

Trial Profile

Open-Label, Part-Randomized Study Designed to Evaluate the PK Profile of Tenofovir Exalidex (TXL) Following Single Dose of Oral Formulations in Comparison to a Reference IR TXL Tablet in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Aug 2018

At a glance

  • Drugs Tenofovir exalidex (Primary)
  • Indications Hepatitis B
  • Focus Pharmacokinetics
  • Sponsors ContraVir Pharmaceuticals
  • Most Recent Events

    • 31 Jul 2018 Status changed from recruiting to completed.
    • 28 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.
    • 28 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top